Lundbeck
Tracked across 3 events · 20 articles · First seen Apr 13, 2026 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Impact: Lundbeck is presenting new data across its neurology portfolio, including bocunebart, eptinezumab, and bexicaserin, at the American Academy of Neurology Annual Meeting 2026, highlighting its commitment to advancing brain disease treatments.
Apr 13, 2026 · 6 articles
Business
Impact: Lundbeck received orphan drug designation in Japan for asedebart, which is a positive development for the company's pipeline and market reach in rare diseases.
May 18, 2026 · 7 articles
Business
Lundbeck announced that the South Korea — Ministry of Food and Drug Safety of South Korea has granted marketing authorization for eptinezumab (Vyepti) for the preventive treatment of migraine in adults. This approval is a…
Impact: Lundbeck received marketing authorization for its migraine treatment, eptinezumab, in South Korea, expanding its global market presence and potential revenue.
May 26, 2026 · 7 articles
100
South Korea — Ministry of Food and Drug Safety granted marketing authorization LundbeckH. Lundbeck receives South...
90
Lundbeck announced approvalH. Lundbeck receives South...
NEWSDESK
Track Lundbeck live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard